Welcome to our dedicated page for Praxis Precision Medicines SEC filings (Ticker: PRAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Praxis Precision Medicines鈥� dense clinical disclosures can feel like navigating ion-channel schematics after midnight. Each 8-K on trial data, every 300-page 10-K, and the constant trickle of Form 4s paint a moving picture of pipeline risk and cash needs鈥攂ut only if you find the right line items. That鈥檚 the problem.
Stock Titan solves it. Our platform ingests every Praxis Precision Medicines quarterly earnings report 10-Q filing, real-time Praxis Precision Medicines Form 4 insider transactions, and each sudden 8-K material event, then delivers AI-powered summaries that explain what changed鈥攊n language as clear as your morning coffee. Search 鈥淲hat does Praxis report in its SEC filings?鈥� or 鈥淗ow to read Praxis Precision Medicines鈥� 10-K annual report鈥� and arrive here: insider trading Form 4 alerts, segment spending breakdowns, and liquidity updates all mapped to the company鈥檚 Cerebrum鈩� and Solidus鈩� programs.
Inside the feed you鈥檒l find:
- Praxis Precision Medicines insider trading Form 4 transactions with context on clinical catalysts
- Praxis Precision Medicines annual report 10-K simplified into key risk factors and cash runway metrics
- Praxis Precision Medicines proxy statement executive compensation cross-linked to R&D milestones
- Praxis Precision Medicines quarterly earnings report 10-Q filing trend graphs and AI commentary
- Praxis Precision Medicines 8-K material events explained against trial timelines
Whether you鈥檙e comparing burn rate quarter-over-quarter, tracking executive stock transactions Form 4, or simply understanding Praxis Precision Medicines SEC documents with AI, our continuously updated dashboard keeps you ahead of the next clinical readout鈥攚ithout combing through endless PDFs.
Praxis Precision Medicines, Inc. (PRAX) filed a Form 4 disclosing that director Dean J. Mitchell received a new stock option grant for 10,520 common shares on 26 June 2025. The option carries an exercise price of $44.04 and expires on 26 June 2035. Vesting occurs in twelve equal monthly installments over one year starting on the grant date. No common shares were bought or sold; this is purely an equity-based compensation award that increases Mr. Mitchell鈥檚 derivative holdings to 10,520 options, all held directly. The transaction is routine and designed to align director incentives with shareholder interests, with minimal immediate balance-sheet or ownership impact on PRAX.
Praxis Precision Medicines (PRAX) 鈥� Form 4 Insider Activity
Director William D. Young disclosed the grant of a stock option for 10,520 common shares on 26-Jun-2025 at an exercise price of $44.04. The option vests in twelve equal monthly installments over one year, beginning on the grant date, and expires on 26-Jun-2035. No open-market purchases or sales of common stock were reported. Following the transaction, Mr. Young beneficially owns 10,520 derivative securities linked to PRAX common shares. The filing was executed on 27-Jun-2025.
Praxis Precision Medicines, Inc. (PRAX) filed a Form 4 disclosing that director Gregory Norden received an option grant on 26 Jun 2025.
- Derivative security issued: Non-qualified stock option covering 10,520 common shares with an exercise price of $44.04.
- Vesting schedule: Vests in twelve equal monthly instalments beginning 26 Jun 2025, fully vested after one year.
- Expiration: 26 Jun 2035 (10-year term).
- Ownership impact: Following the grant, Norden beneficially owns 10,520 derivative securities (stock options) directly; no non-derivative share movement is reported.
The filing represents a routine equity incentive award to a board member and does not indicate any open-market purchase or sale of PRAX shares.
Praxis Precision Medicines, Inc. (PRAX) 鈥� Form 4 insider filing
Director Jill DeSimone received a new option grant on 26 June 2025. The grant covers 10,520 shares of common stock at an exercise price of $44.04 and expires on 26 June 2035. Vesting is scheduled in twelve equal monthly installments over one year beginning on the grant date, aligning compensation with near-term company performance. After this transaction Ms. DeSimone holds 10,520 derivative securities directly. No common-stock transactions, sales, or additional option exercises were reported.
The filing represents a routine equity incentive for a non-employee director and does not change PRAX鈥檚 share count in a material way. The transaction code "A" confirms an acquisition of options rather than an open-market purchase, so immediate cash outlay or insider buy-signal implications are minimal.
Praxis Precision Medicines, Inc. (PRAX) reported a routine insider equity award through a Form 4 filed on 27 June 2025. Director Jeffrey Chodakewitz received a grant of 10,520 stock options on 26 June 2025 at an exercise price of $44.04 per share. The options vest in 12 equal monthly installments over one year beginning the grant date and carry an expiration date of 26 June 2035. No open-market purchases or sales of common stock were disclosed, and Mr. Chodakewitz鈥檚 direct derivative holdings after the transaction total 10,520 options. The filing reflects a standard compensation-related award rather than a change in the director鈥檚 economic exposure to outstanding common shares.
Praxis Precision Medicines, Inc. (PRAX) 鈥� Form 4 Insider Transaction
Director Merit Ester Cudkowicz reported the grant of 10,520 stock options on 26 June 2025. The options carry an exercise price of $44.04 and expire on 26 June 2035. Ownership is recorded as direct.
Vesting schedule: the award vests in 12 equal monthly installments over one year, beginning 26 June 2025, resulting in full vesting by 26 June 2026. Following the grant, the reporting person beneficially owns 10,520 derivative securities; no common-stock transactions were disclosed in Table I.
The filing is routine compensation-related and does not involve any sale or purchase of shares. It primarily signals ongoing alignment of director incentives with shareholder interests and does not immediately affect PRAX鈥檚 capital structure, earnings, or liquidity.
Praxis Precision Medicines, Inc. (Nasdaq: PRAX) filed a Form 8-K detailing the voting results from its 2025 Annual Meeting held on June 26, 2025. A quorum was present and all three management proposals passed.
- Proposal 1 鈥� Election of Class II Directors: Dr. Jeffrey Chodakewitz was elected with 14,596,188 votes for and 2,998,186 withheld; Dr. Merit Cudkowicz received 17,499,300 votes for and 95,074 withheld. Both directors will serve until the 2028 annual meeting. Broker non-votes for each nominee totaled 778,152.
- Proposal 2 鈥� Auditor Ratification: Ernst & Young LLP was re-appointed as independent registered public accounting firm for FY 2025 with 18,358,636 votes for, 7,630 against and 6,260 abstentions (no broker non-votes).
- Proposal 3 鈥� Say-on-Pay (advisory): Executive compensation was approved with 10,671,320 votes for, 6,919,705 against, 3,349 abstentions and 778,152 broker non-votes.
No additional matters were brought before stockholders. The filing is primarily administrative and does not disclose financial performance, transactions, or strategic changes.
FAQ
What is the current stock price of Praxis Precision Medicines (PRAX)?
What is the market cap of Praxis Precision Medicines (PRAX)?
What is the core focus of Praxis Precision Medicines?
Which platforms does Praxis utilize for its drug development?
How does Praxis differentiate itself in the competitive biopharmaceutical market?
What types of disorders is the company targeting with its therapies?
What stage are Praxis' product candidates currently in?
Who are the key collaborators and partners of Praxis?
How does Praxis' approach impact the management of CNS disorders?
